

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : G06F 19/00	A1	(11) International Publication Number: WO 97/27560 (43) International Publication Date: 31 July 1997 (31.07.97)
(21) International Application Number: PCT/US97/01727 (22) International Filing Date: 29 January 1997 (29.01.97) (30) Priority Data: 08/593,446 29 January 1996 (29.01.96) US (71) Applicant: ONCORMED [US/US]; 205 Perry Parkway, Gaithersburg, MD 20877 (US). (72) Inventor: EVANS, Steven; 418 North 38th Street, Omaha, NE 68131 (US). (74) Agents: JONDLE, Robert, J. et al.; Rothwell, Figg, Ernst & Kurz, 555 13th Street, N.W. # 701 East, Washington, DC 20004 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: METHODS FOR IDENTIFYING HUMAN HEREDITARY DISEASE PATTERNS (57) Abstract The present invention relates to a method of determining human hereditary disease risk factors, a method of determining hereditary cancer patterns presenting in cancer family histories, and a method of determining whether a cancer family history represents a hereditary pattern.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

BACKGROUND OF THE INVENTION

Recognition of the role of heredity in cancer has increased steadily over time and is discussed in Lynch et al. *Genetic Epidemiology of Cancer*, Boca Raton: CRC Press, (1989). For example, Lynch et al., *Surg. Clin. Of NA*, 70:753-774, (1990) has estimated that approximately 9% of carcinoma of the breast is consistent with hereditary breast cancer, and an additional 15-20% will be clearly familial. In addition, the potential for gene testing to confirm hereditary cancer has escalated in recent years, with the discovery of genes that cause breast cancer, colon cancer, and several other cancer syndromes. However mass testing of the population with dozens of expensive gene tests is not viable. The most effective way to identify hereditary cancer families has been with a detailed and accurate cancer family tree. It has been noted, that "[a] thoroughly compiled family history of cancer harbors the potential of being the most cost beneficial component of the patient's workup" (Lynch, HT, "Cancer and the family history trail, *New York State Journal of Medicine*, pp. 145-147, April, 1991). From

such a family tree, the patterns of hereditary cancer can be detected by expert clinical oncologists. Subsequently proper surveillance and management may then be ascertained in concert with judicious gene testing, if and when available, to confirm the risk evaluation.

5 Unfortunately physicians generally do not take a detailed cancer family history. One study found that in most cases, "the family history of cancer had either been omitted altogether or reported as negative, despite substantial evidence to the contrary" (Lynch, HT et al. Family history in an oncology clinic: Implications for cancer genetics," *J. AMA*; 242:1268-1272, 1979.). Documentation of the failure to apply
10 proper genetic principles or to obtain necessary family cancer histories has been repeatedly obtained.

 Hereditary cancer pattern recognition has been difficult, given that: 1) there are now over 200 types of hereditary cancer syndromes, 2) the family history relayed from the patient can be "fuzzy" and imprecise, and 3) the variation among all the patterns
15 may have billions of different presentations.

 In the development of expert systems to mimic clinical experts, experts are studied, and guesses or observations are made as to what rules they are applying for specific cases. This process of study may or may not find or recognize rules, is dependent upon the reporting of the expert, and does not automatically create any rule
20 set, but is dependent upon the insights of an observer. It is observer-dependent, not data-dependent. In addition, such construction and validation can require very long periods of time. Since the hereditary cancer field is constantly changing with new patterns uncovered, an expert system may be obsolete by the time it is developed. In addition, usually any one expert does not have the expertise to cover all the known
25 hereditary cancer syndromes, but combining a version of one rule set from one expert with another rule set from another expert may yield inconsistent results. Finally and perhaps most important, any one expert's rule set is just that: the opinion of one expert. There are different philosophies in medicine as to what issues should be factored in, leading to dissension and confusion.

SUMMARY OF THE INVENTION

The present invention relates to a method of determining human hereditary disease risk factors, a method of determining hereditary cancer patterns presenting in cancer family histories, and a method of determining whether a cancer family history represents a hereditary pattern implemented on a computer.

More specifically, the invention relates to a method for determining the existence of a hereditary disease risk in a patient, comprising the steps of: compiling in a computer a database made up of a plurality of records each pertaining to an individual and containing a history of at least one specific disease in a family of that individual, with a plurality of parameters relating to each family member identified in the history; defining a plurality of functions each pertaining to one of the parameters and assigning predetermined weights to the functions based on values of the parameters; for each record in the database, summing the weights obtained for each of the functions to obtain a total value for each of the functions, identifying the record as presenting a hereditary pattern if the total value is above a predetermined threshold, and grouping the identified record into a subset of records; for each record in the database, applying expert knowledge generated rules to independently identify records as presenting hereditary patterns; comparing the independently identified records with the subset of records, and validating defined functions if a predetermined minimum percentage of records in the subset are consistent with the independently identified records; and using validated functions as a recognizer of hereditary disease patterns in a family history of the patient.

The invention also relates to a method wherein the plurality of records contain histories of instances of cancer including breast, ovarian, endometrial, prostate, malignant melanoma and colon cancer.

The present invention further relates to a method including the step of assigning weights to particular attributes used in the functions, and defining attributes as significant in the definition of specific hereditary disease patterns if a minimum percentage of records in the subset are consistent with the independently identified records.

This invention also relates to a method wherein an additional record is created in the database for each relative of the individual who is identified as having had the disease.

DETAILED DESCRIPTION OF THE INVENTION

5 In order to provide an understanding of several of the terms used in the specification and claims, the following definitions and explanations are provided:

Data Mining: As used herein, the term data mining is intended to mean a procedure that takes given examples of a specific condition and calculates rules that define set membership. For example, if individual history patterns were already
10 classified as to whether they are hereditary or not, data mining would select factors within each pattern which imply the hereditary condition. In Table 1, the following condition are used as an example:

Table 1

15 Patient List	F1 = Mother had cancer	F2 = Father had cancer	F3 = Mother's sister had cancer	F4 = Father's brother had cancer	Is this case an example of a hereditary cancer pattern?
John	yes	yes	no	no	no
20 Sally	yes	no	yes	no	yes
Fred	no	yes	yes	no	no
Joe	yes	no	no	yes	no
Ann	no	yes	no	yes	yes

25 Then any data mining procedure would be able to find the two rules:

If F1 and F3

-or-

If F2 and F4

THEN (meeting either rule) implies a "hereditary cancer pattern."

30 One uses the pathway-searching power of a comparison (data mining) algorithm to find predictive patterns. Note that in the instant invention, there is no indication

which, if any, are the "example cases" of hereditary cancer in the data in order that one might obtain a logical rule set from data mining methods.

Expert Rule: The term expert rule is intended to mean a set of rules, each of which is comprised of logical measurable conditions, in mathematics, called a testable predicate which is an expression or condition that can be determined to be true or false based on measurement or data, wherein these conditions are joined by logical operators, including the operators AND, OR, and NOT, having the usual logical meaning. Given an example of the pattern about which the rule is concerned, one can examine the measurable characteristics of a pattern and ascertain whether it satisfies all the conditions of one or more of the rules in an expert rule set.

Recognizer: The term recognizer is intended to mean a rule set for a class of patterns for which any member of the class satisfies one or more of the rules in the rule set. For example, a set of reasonable conditions might be:

- a) for a specific person "p", there was a colon cancer in a first-degree relative of that person,
- b) for a specific person "p", there was a colon cancer occurring before age 35 in a first-degree family member relative
- c) for a specific person "p", there were three or more cases of colon cancer in first or second-degree relatives

And one rule might be: (a) AND ((b) OR (c))

The meaning of this rule is that if a person had a first-degree relative with colon cancer and that person had either a first degree relative with colon cancer occurring before the age of 35 or had three or more cases of colon cancer in first or second degree relatives, then that person's pattern meets or satisfies the rule. If this is one of the rules for a recognizer of hereditary colon cancer, then the person's pattern is said to be classified as a member of the recognized pattern set i.e., the pattern is a hereditary colon cancer pattern. If any member of the class of patterns constituting hereditary colon cancer were to fit the rule above, the rule above would then be the rule set or recognizer of hereditary cancer, although obviously the set usually has many different rules in

order to successfully classify all possible presentations of the pattern. The actual recognizer for hereditary colon cancer has approximately 15 complex rules, each with several composite conditions or elements.

Neural Nets: The term neural nets is intended to mean mathematical algorithms which can assign weights to attributes which describe a situation so that a presentation of attributes can be tested to see if it qualifies as an example of the thing being recognized. Like data mining, development of neural nets assumes there is an assignment to the individual descriptions in the database indicating whether an entry is a member of the set of things being recognized or not. In the simplest form, for a case presented to a neural net, the outcome of a neural net is a value, which if greater than a certain amount, signifies the case is confirmed as true. The net does not however provide a rule or disclose what the logical relationship is among the attributes which led to the assignment of "true." Hence the net provides no explicit clinical evaluation, but is essentially like litmus paper which signals a positive or negative result. In Table 1, a neural net approach could yield the equation

$$\text{IF } a(F1 + F3) + b(F2 + F4) \geq 4$$

THEN "signal (possible) hereditary cancer pattern"

where $a=2$, $b=2$, each F is 1 or 0 depending on whether it is true or false.

The method of the present invention uses a computer database of cancer family histories, and from such information, automatically creates "IF-THEN" rule-based expert systems capable of determining or testing whether a cancer family history represents a hereditary cancer pattern. The term "recognizer" is used to signify the end result of the method's implementation. Unlike neural network software applications or data mining software applications, the present invention does not presume any definition or marker in the data indicating whether any cancer family history represents an example of a hereditary cancer family.

The instant invention creates a pool of likely hereditary cancer candidates among the cancer family history cases in the database and then extrapolates from these cases

the nature of hereditary cancer patterns. Core genetics principles are employed which tend to characterize cases that would be good candidates for representing hereditary cancer. For example, one such principle is that typically hereditary cancer arises much earlier in the patient's life than does non-hereditary cancers. The application of a set of

5 key principles will divide the set of all cases into those which reflect some mix of these principles, beyond a threshold, and those that do not. The degree to which the principles apply in a case is the extent to which a case tends to be a candidate to represent a hereditary pattern. All such cases that exceed some measurable threshold will be declared confirmed candidates for representing a possible hereditary pattern.

10 A second stage of the present invention is to take the cases that are confirmed candidates and then determine both the genetic principles which classify the confirmed candidates as well as the patterns of cancers in these cases which characterize the candidates. Specifically two sets of rules are determined which classify the cases into various composite pattern sets wherein each rule describes one or more patterns. This

15 stage uses software called data mining techniques in order to obtain computer-generated rules which group or classify the candidate cases, using first the genetic principles and then the cancer family history patterns. In the first instance, the genetic principles characterize the candidate cases by a rule set in which the use of a genetic principle in the set indicates that this principle is a factor in the overall determination of hereditary

20 cancer for the index cancer designated. These second rule set is a refining definition based on cancer patterns for the candidate cases. Each rule in the second set is examined, and the specific cancers used in each rule become the cancers which characterize the index cancer, e.g., endometrial cancer is a coincident cancer in rules that characterize colon cancer.

25 In the third stage, these coincident cancers are combined with the candidate-defining genetic principles to create the complete recognizer which is a composite set of clinically oriented defining rules.

One method of the present invention includes the following steps:

Step 1. The first step is to obtain a database which contains the cancer family

history of cancer-affected individuals. There is nothing special about the form of the data, except that the data must contain the cancer family history of individuals. The essence of the information needed for each person (called a "proband") in the initial database is the following information concerning the cancer family history:

5

a) All first and second degree relatives of the proband are labeled, and each person is identified who has had cancer along with how he or she relates to the proband (such as, "it is the proband's mother's sister").

10

b) Enumeration of the types of cancer each blood relative of the proband has had, and the age of the person when he or she was diagnosed.

Step 2.

15

Second, for every individual in the proband's cancer history who has had cancer, another cancer record is created describing the whole cancer family history relative to that person. For example, if a woman as proband had breast cancer and her mother did also, in addition to this master record, a second new record would be added for the mother as proband, indicating she had a daughter who had breast cancer. All such new records are added for both the maternal and the paternal side. Thus every entry represents some cancer-affected person indexed by a specific cancer. If a person's family history indicates more than one cancer, the family history permits the definition of multiple entries with one entry for each cancer type exhibited. What this first key step does is multiply the individual case histories of patients, with all the variations that can occur, into a richer universe of patterns. This transposition of patterns from all points of the family view multiplies the universe of pattern considerations into a set many times greater than the first, significantly expanding the ultimate fidelity of the recognizer created. It also expands the variations on how cancer patterns may be viewed and considered.

20

25

Step 3.

Once the individual cancer family histories are expanded into many different cancer family patterns, a specific cancer or cancers, of interest to be recognized is specified, e.g., breast cancer, and all entries in the newly expanded database of patterns which are indexed by the selected cancer are retrieved. Although several cancers may be picked at once with multiple cancers being an additive case, we shall give this description as if only one index case was selected, merely for ease of explanation.

Step 4.

Next, a further subset of all the cancer histories concerned with the cancer of interest is selected which shall represent candidate hereditary cancer cases from which common patterns are extrapolated. This is accomplished by positing a set of descriptors or genetic principles which typically are known to be involved in hereditary disease. One such descriptor is "early-age-of-onset," since hereditary cancers tend to occur earlier than normal. Each descriptor is quantified. For example, if a cancer family history has a cancer occurring before the age of 50, one point is assigned; if there is a cancer occurring below the age of 45, two points are assigned; and if one occurs before the age of 35, three points are assigned. In the instant invention five such descriptors have been employed although the method in general could be instantiated with as many principles as desired. These genetic principles can include (1) early age of onset, (2) presence of cancer over several generations, (3) several cancers in the same generation, (4) multiple cases of the same cancer occurring, and (5) a high proportion of the relatives in the family expressing cancer. Each is quantified assigning increasing points the more the principle is expressed in the case history. Cases with a certain total score or higher are then labeled as candidates for the group that represents a hereditary cancer pattern and are then selected for further analysis. Although the principles have been quantified, the actual point

assignments can be changed without changing the essential process. In addition, other principles can be added without changing the essential process.

Step 5.

5

The subset of candidates from step 4 is labeled "true" for the purposes of now running off-the-shelf data mining software, such as Datalogic/R1.3 from Reduct Systems, Inc., which hypothesizes IF-THEN rules to describe how attributes of the marked "true" cases can characterize the "true" set. Each member of the "true" set has two different sets of defining attributes.

10

- a) Genetic principles with individual point totals indicating how each principle contributed to the overall score, as well as a total score above a threshold value, and
- b) The occurrence of different cancers in the family for each case of the "true" set.

15

The data mining software is used first with one set of attributes, the genetic principles, and then with the other, the occurrences of cancer. The outcome of such a procedure is a set of rules using the attributes (genetic principles in the first case, cancer pattern types in the second) in which these attributes characterize the "true" set as much as possible.

20

For example, a rule using the genetic attributes might be "IF a case accrues at least 6 points on early-age-of-onset plus at least 3 points for "multi-generational cancers", then 100% of the time such a case is one of the "true" cases," as "true" is defined by being a candidate as derived in step 4. Similarly, a rule for the cancer patterns might be, "if there are at

25

least 2 first-degree family breast cancers, such as in your mother or sister, and at least 2 second-degree breast cancers such as in two aunts, then 100% of the time such a case is one of the "true" cases as "true" is defined by being a candidate as derived in step 4. Data mining software is run for first the genetic principles and then the cancer pattern

expressions in the family as defining characteristics. An arithmetic calculation is then made to determine what percent of all the "true" cases (i.e., the percent of the candidate set from step 4) meet any one rule. A rule that is met by at least 5% of all true cases, which is then defined as a significant rule, is examined, and all attributes in such significant rules are listed and are determined to be significant risk factors for the index cancer.

The attributes that are significant from the genetics principles list are the genetic principles which are pertinent to the selected index cancer and its pattern of presentation, while the cancers which are listed in the cancer-patterns significant rules are the pertinent cancers for the selected index cancer in question.

The outcome or output from step 5 is two sets of attributes which are comprised of entries from the genetic principles list and the cancers list. The aggregate of the attributes found in the rules that meet the 5% rule are defined to be the correlated genetic principles and cancer patterns which are coincident with and can characterize the selected index cancer pattern under consideration.

Step 6. Finally, data mining software is run again, marking as of interest the enumerated significant genetic principles and the significant cancer patterns from step 5 which shall characterize the "true" set in order to get a combined rule set of both genetic principles and cancer patterns, which characterizes the "true" set. The software derives a set of rules which uses the composite attributes that have been derived by this process (as per step 5), and which characterize the "true" set as defined. The set of all rules in this step 6 which are significant (i.e., 5% or more of the "true" set meet the rule) constitute the hereditary cancer rules which recognize the hereditary cancer pattern for the index cancer selected. Thus the set of all such rules in this stage is the hereditary cancer recognizer for the

index cancer originally picked. The cancer attributes which arise in step 6 in the final set constitute the final output set of associated cancer attributes and are determined to be the highest correlated cancers for the index cancer. These associated cancers, determined to be the highest correlated cancers, are the cancers used to instantiate any rule.

Step 7. For any single new cancer family history, if the history can meet any one of the defining rules from the final output of step 6, this cancer family history is determined to exhibit a hereditary pattern.

These above seven steps create defining patterns which characterize the index cancer at issue. This process is independent of any diagnostic hereditary cancer history labeling or assignment. It is automatic in that following the process leads to a rule set if one exists.

The following implementation was conducted:

1. The master file from HCI was combined, unified, and made compatible with the theoretic approach proposed, with all identifiers removed to preserve total confidentiality as shown in Example 1.
2. A dBase program was used that permits us to select cancer type(s) t from the master file and permute records through transposition of genetic histories as shown in Example 2.
3. Core principles were defined which assign a numerical ranking to every case, ranking the case (with value v) in terms of its candidacy for hereditary status as shown in Example 3.
4. A dBase program was used that applies the set of principles in order to define a set of hereditary candidates and then delivers these to our data mining software. Then, as shown in Example 4, data mining software was used to determine clinical rules which further characterize the interesting candidate cases by their family pattern of cancer.
5. Experiments have been run with values v for cancer type t in concert with the data mining program and have created a class of recognizers as shown in

Examples 5-11.

6. Experiments and refinements of the process as well as evaluating the recognizers for usefulness have been conducted as shown in Examples 12-17.

For example, focusing on colon cancer, one process of the present invention
5 yields a set of rules (a recognizer) so that 100 % of all the cases in the independent files available to the experimenters, labeled hereditary to date by medical experts are correctly labeled by the recognizer.

We determined the nature and extent of the hereditary colon cancer cases which are not recognized, if any, in further experimentation and how to adjust the process so
10 that the automatically constructed recognizer has greater selectivity and sensitivity. We have also replicated this effort to analogous recognizers for breast cancer, malignant melanoma, and pancreatic cancer.

EXAMPLES

The following examples are provided to further illustrate the present invention
15 and are not intended to limit the invention beyond the limitations set forth in the appended claims.

Example 1

Developing a Database

A database of clinical cases was converted into an information source that
20 permits the development of appropriate rules. The database was obtained from the Hereditary Cancer Institute (HCI) of the Creighton University School of Medicine, Omaha, Nebraska. This database had cases describing patient cancer family data. There was not an independent assessment in the database which validated that a patient in the database is in fact a hereditary-cancer-affected person. The database represented
25 people who contacted HCI, and so we believed there were some hereditary families in the database. However this database did not have a hereditary cancer assignment of "true" or "false" regarding each case (in which true = a hereditary cancer carrier), although such an assignment is needed for either traditional neural network or data mining methodology.

Example 2**Expanding An Initial Database into Varied Patterns**

The HCI database was modified to multiply our case patterns as much as possible. This process is described below:

5 Let R be all records in the currently available HCI database of cancer patients. There were about 56,000 such cases, comprised of sporadic cases, hereditary, familial, putative, and unknown designation of 45 different types of cancer, although we do not know per individual which designation applies. First these records are split into two separate cases, one "record" being the patient with the information describing his or her
10 maternal side, and another record describing the paternal side. This split makes analysis much easier, and results in two genetically separate patterns to consider for each original client in the database. This new database of approximately 100,000 patterns is R'. Second, we took R' and for every cancer case in R' we looked at the family of each patient or client, identified any cancers occurring in another family member, and wrote
15 *another* record describing the cancer history from that family member's point of view. Thus the cancer-affected individuals in the family are viewed as proband themselves, with the record properly reconfigured to reflect this history. For example, if a female patient had breast cancer, and the patient's mother and daughter did also, then additional records would be added to the database from the viewpoint of the person's affected
20 mother and daughter. First, a record would be added for the mother, indicating she had a daughter and a granddaughter with breast cancer. Then another record would be added for the daughter, indicating she had a mother and grandmother with breast cancer. If the mother had a sister with colon cancer, yet another record would be added for this sister, indicating she had colon cancer, had a sister with breast cancer, a mother with
25 breast cancer, and a niece with breast cancer. In this way, a pattern can be expanded into the many ways the pattern might be viewed or presented. We say we "pivot" on each cancer family member, adding the alternate perspective of that member to the database. Once complete, we now have R₀, the "pivoted" database for R'. This strategy increases our theoretical pattern set to perhaps 500,000 patterns.

Example 3**Defining Genetic Principles**

We presented the five basic broad-level genetic principles that may apply in any hereditary pattern, which were:

- 5 a. Inheritance may show up more than once in the same generation (horizontal or generational inheritance). This principle will be made precise as a function f_1 in the application example below and is abbreviated GENLINE in the computer output.
- 10 b. Inheritance may show up from the prior generation to a subsequent generation (which we call inter-generational or vertical inheritance). This principle will be made precise as a function f_2 in the application example below and is abbreviated VERLINE in the computer output.
- 15 c. There may be numerous instances of various (different) manifestations of the pattern over multiple generation (general intensity). This principle will be made precise as function f_3 in the application example below and is abbreviated INTENSITY in the computer output.
- 20 d. There may be numerous instances of the same manifestation of the pattern over multiple generations so that there is a specific intensity of some specific manifestation. This principle will be made precise as function f_4 in the application example below and is abbreviated SPECINTEN in the computer output.
- 25 e. Since it is genetically based, it occurs sooner (early age of onset) in the age of the organism expressing the pattern (i.e., as soon as the genes can begin expressing themselves) rather than at later ages such as patterns caused by external (i.e., non-genetic events whose probability of occurrence can build over time and thus more and more likely occur as more and more time passes (late age of onset). This principle will be made precise as a function f_5 in the application example below and is abbreviated EARLY in the computer printout.

We define a quantifiable assignment of values for the above set of five genetic attribute features which help distinguish a potential hereditary pattern.

We denote \bar{x}^k as a single record of some person or case in the Ro, where the bar over the x indicates the x is a vector of information containing the family cancer history for relatives for each person x, and the k indicates the kth person in the total database Ro. We will define five functions (f_i) of \bar{x}^k as follows:

$f_1(\bar{x}^k)$: Generational Cancer - this attribute states that one or more cancers on the same generational line, on the same side, is an interesting attribute. We assigned the value:

10 $f_1(\bar{x}^k) = 1$ if there is one cancer of one type on one generational line.

$f_1(\bar{x}^k) = 2$ if there are two cancers of the same type on the same line.

$f_1(\bar{x}^k) = 3$ if there are three or more same cancers on the same line.

$f_2(\bar{x}^k)$: Inter-generational cancer - this attribute states that one or more cancers, on the same generational side, between generations, is an interesting attribute. We assigned:

15 $f_2(\bar{x}^k) = 1$ if there is one cancer on one generational line.

$f_2(\bar{x}^k) = 2$ if there are 2 identical cancers on 2 different generational lines.

$f_2(\bar{x}^k) = 3$ if there are three or more identical cancers among generations.

$f_3(\bar{x}^k)$: Overall cancer intensity - this attribute states that a large percent of the relatives having cancers on the same side of the family (not counting children) is an interesting attribute. We assigned:

20 $f_3(\bar{x}^k) = 1$ if up to 33% of the family on the same side had cancer.

$f_3(\bar{x}^k) = 2$ if up to 66% of the family on the same side had cancer.

$f_3(\bar{x}^k) = 3$ if more than 66% of the family on the same side had cancer.

25 $f_4(\bar{x}^k)$: Specific cancer intensity - this attribute states that a large number of identical cancers on the same side of the family is an interesting attribute. We assigned:

$f_4(\bar{x}^k) = 1$ if there is more than one identical cancer on the same side.

$f_4(\bar{x}^k) = 2$ if there are more than two identical cancers on the same side.

$f_4(\bar{x}^k) = 3$ if there are more than 3 identical cancers on the same side.

$f_5(\bar{x}^k)$: Early age of cancer onset - this attribute states that early age of onset of cancer is an interesting attribute. We assigned:

$f_5(\bar{x}^k) = 1$ for each cancer diagnosed by the age of 50.

5 $f_5(\bar{x}^k) = 2$ for each cancer diagnosed by the age of 45

$f_5(\bar{x}^k) = 3$ for each cancer diagnosed by the age of 35.

Using the five principles or functions above, we apply each function to each case record to assign points depending on the data contained in each record of the case under review. The more points, the more the case is very serious in that it is reflecting an example of a hereditary inheritance. We add the five functional values together to get a total sum (and we may multiply any one of the functions times a weight if we wish to emphasize that attribute more than another. A specific point total is selected, and for all cases of the index cancer that is selected (e.g., colon cancer proband cases) that accrue these many points or more, we label this the defining subset from the larger set which will be used to define the recognizer. This set of cases whose point total is above a threshold is the "true" set for purposes of using standard data mining algorithms to characterize the cases in the set. Formalistically, for our colon cancer recognizer, we assign the value "true" to a case x in the database if:

20
$$\sum_{i=1}^5 a_i f_i(x) \geq v$$

for a threshold value v and for a_i where a_i is any numerical weight for f_i .

Example 4

25 As noted in Example 2, a database is obtained and the individual cases permuted so that variations in patterns are obtained. As per Example 3, each individual patient history (or case) is evaluated in terms of how it meets each of the hereditary principles (in the instant case, by a computer program). Example 3 shows how, for an instant application, numeric values are provided with an assignment strategy so that a case
30 accrues points depending on how many cancers there are in the family, the type and extent, etc. All cases that pass a selected threshold value in Example 3 are the candidate

(or "true" cases) for purposes of this invention. The database with the true cases marked as such, and the other cases marked false, is now fed into a standard data mining package (in the instant case, we use DATALOGIC-R/version 1.3 from Reduct, Inc.) Along with, for each case, the specific numeric values for each of the five hereditary principles that each case accrued. The data mining algorithm is directed to first characterize the true cases in terms of the hereditary principles. For the actual database of 56,000 cases from HCI and for all the permutations of cases as described, when focusing on colon cancer cases the following results were obtained in the copy of the computer printout below (where the symbol \geq means "greater than or equal to" and the symbol $<>$ means "strictly less than or strictly greater than"):

```

1 | | | { [EARLY>=6] & [SPECINTEN>=2] & [GENLINE>=2] & [VERLINE>=1]
2 | OR | | { [EARLY>=6] & [SPECINTEN>=3]
3 | OR | | { [INTENSITY<>1] & [EARLY>=6]
4 | OR | | { [EARLY>=9]
5 | OR | | { [EARLY>=6] & [SPECINTEN>=2] & [GENLINE>=3]
6 | OR | | { [EARLY>=6] & [GENLINE>=3] & [VERLINE>=1]
7 | OR | | { [EARLY>=6] & [VERLINE>=2]
8 | OR | | { [INTENSITY<>1] & [EARLY>=3] & [SPECINTEN>=3] & [GENLINE>=2] & [VERLINE>=1]
9 | OR | | { [INTENSITY<>1] & [SPECINTEN>=3] & [GENLINE>=2] & [VERLINE>=2]
10 | OR | | { [EARLY>=3] & [SPECINTEN>=3] & [GENLINE>=3] & [VERLINE>=2]
11 | OR | | { [INTENSITY<>1] & [EARLY>=3] & [SPECINTEN>=2] & [VERLINE>=2]

```

In these 11 rules, 90.21% of all colon cancer cases among the "true" cases can be characterized. This means over 90% of all the "true" cases meet one of these 11 rules. Since there are 1,020 "true" cases, the 5% significance rule means that 5% of 1,020 or 51 cases at the minimum must meet any one rule for the rule to be counted as significant. One of many standard reports from the software gives these figures: Rule 1 - 686 cases; Rule 2 - 713 cases; Rule 3 - 330 cases; Rule 4 - 455 cases; Rule 5 - 720 cases; Rule 6 - 652 cases; Rule 7 - 298 cases; Rule 8 - 368 cases; Rule 9 - 207 cases; Rule 10 - 305 cases or Rule 11 - 8 cases.

Applying the 5% significance rule, rule 11 is omitted, and the rest remain.

Inspecting the attributes (the hereditary principles) which occur in the 10 viable rules, we find all but "INTENSITY" are used. INTENSITY occurs only with a \leq sign in all rules and since one of the viable choices is "strictly less than 1", the value of zero is a choice, meaning zero INTENSITY is a permissible condition (i.e., no INTENSITY). So this attribute falls away, and the remaining are significant.

This procedure is repeated using all of the cancers that occur in the family histories of all the cases. The results are again presented below from the same software package. In this run, only the twelve rules 1, 2, 3, 4, 6, 7, 8, 9, 10, 11, 13 and 14 had more than 51 cases meeting the specific rule.

```

1 | | | {CA14_A<1} & {4<= CA1_A <=14} & {CA1_B>=2}
2 | OR | | {CA1_A>=6} & {1<= CA1_B <=7}
3 | OR | | {4<= CA1_A <=14} & {1<= CA1_B <=7} & {CA2_A>=1}
4 | OR | | {4<= CA1_A <=14} & {CA9_B>=1}
5 | OR | | {CA2_A>=1} & {CA9_B<=0 or CA9_B>=2} & {CA2_B>=1}
6 | OR | | {CA14_A<1} & {4<= CA1_B <=7}
7 | OR | | {2<= CA1_B <=7} & {CA2_A<=0 or CA2_A>=2} & {CA2_B>=1}
8 | OR | | {4<= CA1_A <=14} & {CA2_B>=1}
9 | OR | | {4<= CA1_A <=14} & {CA2_A>=2} & {CA24_A<=0 or CA24_A>=3}
10 | OR | | {CA2_B>=3}
11 | OR | | {CA1_A>=8} & {CA2_A>=1}
12 | OR | | {CA42_A>=1} & {1<= CA1_B <=7}
13 | OR | | {CA1_A<=3 or CA1_A>=8} & {CA1_B>=3} & {CA2_A<=0 or CA2_A>=2} & {CA9_B<=0 or CA9_B>=2}
14 | OR | | {CA1_A>=6} & {CA24_A>=1}
15 | OR | | {CA1_B>=2} & {CA2_A>=1} & {CA9_B<=0 or CA9_B>=2}
16 | OR | | {CA3_A<1} & {1<= CA1_B <=7} & {CA2_A>=1} & {CA6_B>=1}
17 | OR | | {CA2_A>=2} & {CA6_B>=1}
18 | OR | | {CA6_B>=1} & {CA24_A>=1}
19 | OR | | {CA3_A>=1} & {4<= CA1_A <=14} & {CA2_A<=0 or CA2_A>=2}
20 | OR | | {CA3_A>=1} & {CA1_A>=6}
21 | OR | | {CA1_A<=3 or CA1_A>=8} & {CA2_A>=2} & {CA24_A>=1}
22 | OR | | {CA1_B>=2} & {CA9_B>=1} & {CA2_B<=0 or CA2_B>=3}
23 | OR | | {CA3_A<1} & {CA18_A>=1} & {CA6_B>=1}
24 | OR | | {4<= CA1_A <=14} & {CA2_A>=1} & {CA24_A>=1}

```

20

26 OR | |{CA14_A>=1} & {CA9_B>=1}
 27 OR | |{CA1_A>=6} & {CA2_A>=1} & {CA18_A>=1}
 28 OR | |{CA3_A>=1} & {1<= CA1_B <=7} & {CA2_A<=0 or CA2_A>=2}
 29 OR | |{CA14_A>=1} & {CA2_B>=1}
 30 OR | |{CA2_B>=3}
 31 OR | |{3<= CA1_B <=7} & {CA18_A>=1}
 32 OR | |{CA14_A>=1} & {10<= CA1_A <=14}
 33 OR | |{CA3_A>=1} & {CA9_B>=1}
 34 OR | |{CA1_B>=4} & {CA2_A>=1}
 35 OR | |{CA1_A>=15}
 36 OR | |{CA3_A<1} & {CA18_A>=2} & {CA24_A<=0 or CA24_A>=3}
 37 OR | |{CA14_A>=1} & {4<= CA1_A <=14} & {CA2_A>=1} & {CA18_A<=0 or CA18_A>=2}
 38 OR | |{CA42_A<1} & {CA14_A<1} & {CA1_A>=6} & {CA18_A>=1}
 39 OR | |{CA2_A>=1} & {CA6_B>=2}
 40 OR | |{CA3_A>=1} & {CA18_A<=0} & {CA6_B>=1}
 41 OR | |{CA14_A>=1} & {CA18_A>=2}
 42 OR | |{4<= CA1_A <=14} & {CA24_A>=3}
 43 OR | |{CA3_A>=1} & {CA18_A>=2} & {CA24_A>=1}
 44 OR | |{CA18_A>=1} & {CA24_A>=3}
 45 OR | |{CA2_B>=1} & {CA6_B>=2}

Looking at the specific cancers that occur in these rules, we see the following
 codes (and their meaning) survive the 5% rule (the designation of A or B after a code
 such as CA1 for colon cancer indicates a first-degree relative if there is an A - or a
 second-degree if there is a B):

CA1 - colon cancer
 CA2 - endometrial cancer
 CA9 - stomach cancer
 CA24 - ovarian cancer
 CA14 - pancreatic cancer

These five cancers in the rules above characterize nearly 70% of all the cases.
 Since we now have characterized the significant principles and significant cancers that
 can classify the "true" cases, we run the data mining software one more time marking
 just these principles and cancers to be used in combination as the elements of the

permissible rules. Data mining algorithms let you specify what attributes you wish to use in classifying the "true" cases, and since we have derived in the two steps above the key elements, we are ready for the final run. The results are given below:

```

1 | | | { [EARLY>=6] & [SPECINTEN>=3]
5 | 2 | OR | { [GENLINE=3] & [EARLY>=6] & [SPECINTEN>=2]
3 | 3 | OR | { [GENLINE=3] & [EARLY>=6] & [VERLINE>=1]
4 | 4 | OR | { [EARLY>=9]
5 | 5 | OR | { [EARLY>=6] & [SPECINTEN>=2] & [VERLINE>=1] & [CA1_B<=0 or CA1_B>3]
6 | 6 | OR | { [EARLY>=6] & [VERLINE>=2]
7 | 7 | OR | { [GENLINE=3] & [EARLY>=3] & [SPECINTEN>=3] & [VERLINE>=2]
8 | 8 | OR | { [EARLY>=3] & [CA1_A>=6] & [VERLINE>=1]
10 | 9 | OR | { [GENLINE=3] & [EARLY>=3] & { 4<= CA1_A <=9 } & [VERLINE>=1] & { 1<= CA1_B <=5 }
10 | 10 | OR | { [GENLINE=3] & [EARLY>=3] & [SPECINTEN>=3] & [CA1_A<=3 or CA1_A>=8] &
| | | { [CA2_A>=1]
11 | 11 | OR | { [GENLINE=3] & [EARLY>=3] & [VERLINE>=2] & { 1<= CA1_B <=5 } & [CA2_A<=0 or
| | | [CA2_A>=2]
12 | 12 | OR | { [EARLY>=3] & [SPECINTEN>=3] & [CA2_A>=2]
13 | 13 | OR | { [EARLY>=3] & [CA1_B>=2] & [CA2_A>=1]
15 | 14 | OR | { [GENLINE=3] & [EARLY>=3] & [CA1_B>=2]
15 | 15 | OR | { [EARLY>=3] & { 8<= CA1_A <=9 }
16 | 16 | OR | { [GENLINE=3] & { 4<= CA1_A <=9 } & [VERLINE>=2] & [CA2_A>=1]
17 | 17 | OR | { [SPECINTEN>=3] & [CA1_A<=3] & [VERLINE>=2] & [CA1_B<=0 or CA1_B>=3] &
| | | { [CA2_A<=0 or CA2_A>=2]
18 | 18 | OR | { [EARLY>=3] & [CA1_B>=6]
19 | 19 | OR | { [GENLINE<>3] & [SPECINTEN>=3] & [VERLINE<=1] & [CA2_A>=1]
20 | 20 | OR | { [GENLINE<>3] & [EARLY>=3] & [SPECINTEN>=2] & [VERLINE>=2] & [CA1_B<=0 or
21 | 21 | OR | { [EARLY>=3] & [SPECINTEN<=1] & [VERLINE>=2] & [CA1_B<=0 or CA1_B>= 3] &
| | | { [CA2_A>=1]

```

We again apply the 5% rule to get the final, significant rule set. All rules taken together characterize more than 93% of all of the true cases, indicating that this rule set very strongly classifies the true set. Looking at the cases that meet each rule, the first 16 rules meet the 5% cutoff, and the remaining do not. Inspection of the cancers which occur in these 16 rules yields just two: CA1 and CA2 (colon and endometrial cancer). Since this is the colon cancer recognizer, it is a tautology that added colon cancers will define a hereditary condition. Thus the next, non-colon cancer occurring, endometrial

cancer, is identified as the most highly correlated cancer to colon cancer, according to this process (a true fact). To give a single interpretation of a rule, consider rule 8. Rule 8 states that IF there are at least 6 or more first degree colon cancers in the family history (CA1_A>=6) AND there are at least two different generations having either a
 5 colon or endometrial cancer (VERLINE >=1) AND at least 3 points accrue from the hereditary principle of an early age of onset (e.g., either 3 cases under 50, or 1 under 50 and 1 under 45, or 1 under 35, etc), THEN this rule is met by such a case history and the case pattern is one of hereditary colon cancer.

Example 5

10 Hereditary Breast Cancer Recognizer Results

An automated recognizer has been created for hereditary breast cancer. The essence of the hereditary breast cancer recognizer is that the recognizer hypothesizes that the fundamental "issues" in hereditary breast cancer are comprised of:

- * breast,
- 15 * breast - ovarian,
- * breast - endometrial;
- * breast - prostate, and
- * breast - colon cancer patterns.

When just the maternal side was considered, interestingly, there was a somewhat
 20 different recognizer defined than when the paternal side was considered. Specific rules with minimum number of cases are given by the defined (maternal side only) recognizer, involving

- (1st degree breast cancer)
- (1st degree breast) + (2nd degree breast cancer)
- 25 (1st degree breast) + 1st or 2nd degree prostate)
- (1st or 2nd degree breast) + (1st degree ovarian) + (1st or 2nd degree colon)
- (1st degree breast) + (2nd degree breast) + (1st or 2nd degree colon)

These rules are totally numerically precise e.g., one numerically allowed pattern

of "early age presentations" requires either one breast cancer before the age of 35 with another before the age of 45; another acceptable "early age presentation" would be two before the age of 45 and one before the age of 50. It is also important to observe that each rule derived is in effect a family of rules with a wide number of variations which are precisely specified for different values of variables in each rule.

Example 6

Predicted Syndromes

Associated syndromes for each cancer type *t* are summarized below. For each cancer type *t*, the associated cancers that are significant in support of a hereditary pattern are listed in Table 2.

Table 2

Colon	Melanoma	Pancreatic
endometrial/uterine	small intestine	ovarian
kidney	cervix	stomach
stomach	lung	brain
pancreas	stomach	lung
lung	lip	tongue
ovarian	urinary bladder	prostate
	pancreatic	lip
Breast-maternal	Breast-paternal	Ovarian
ovarian	ovarian	breast
colon	prostate	endometrial/uterine
prostate	endometrial/uterine	colon
endometrial/uterine	colon	lung
	lung	prostate
	stomach	

The most highly correlated cancers for various cancer types are summarized below in Table 3.

Table 3

Cancer Type	Key Correlated Cancer
colon	endometrial
breast-maternal	ovarian
breast-paternal	ovarian

ovarian
pancreatic
melanoma

breast
ovarian
small intestine

Although a single key associated cancer can be easily linked to each cancer type,
5 the other cancers that support or reinforce a type suggest a syndrome nonetheless. For
example, the results predict the following combinations for ovarian and breast cancer as
shown in Table 4:

Table 4

	Ovarian Syndromes	Breast Syndromes (maternal side only)
10	ovarian-breast	breast-ovarian
	ovarian-endometrial	breast-endometrial
	ovarian-colon	breast-colon
	ovarian-prostate	breast-prostate
	ovarian-lung	

15

Example 7**Ovarian Cancer Pattern Rules**

A person with ovarian cancer has a hereditary cancer pattern if there are
additionally at least the following:

Two or more 2nd-degree ovarian cancer cases

20

or

One 1st-degree ovarian & two 1st-degree breast cancer cases

or

Two 1st-degree breast & One 1st-degree endometrial cancer

Example 8

25

Breast - Maternal Side

A person with breast cancer has a hereditary cancer pattern if there are
additionally at least the following:

Two 1st-degree breast cancers & two 2nd-degree breast cancers (all on the
maternal side)

30

Or

Two 1st-degree breast cancers & one 2nd-degree breast and one 2nd-degree

colon cancer (all on the maternal side)

Or

One 1st-degree breast cancers & one 2nd-degree prostate cancer (all on the maternal side)

5

Example 9

Breast - paternal side

A person with breast cancer has a hereditary cancer pattern if there are additionally at least the following:

10 Three 1st-degree breast cancers & one 2nd-degree breast cancer (all on the paternal side)

Or

Two 1st-degree breast cancers & one 2nd-degree ovarian cancer (all on the maternal side)

15

Example 10

Pancreatic Cancer

A person with pancreatic cancer has a hereditary cancer pattern if there are additionally at least the following:

Two 1st-degree pancreatic cancers & two 2nd-degree pancreatic cancers

or

20 Three 1st-degree pancreatic cancers & one (either 1st-degree tongue or 1st-degree melanoma)

Or

Two 1st-degree brain cancers

or

25 One 2nd-degree stomach cancer

Example 11

Melanoma

A person with melanoma has a hereditary cancer pattern if there are additionally at least the following:

26

Two 1st-degree melanoma & one 1st-degree lung cancer

or

Four 1st-degree melanomas

or

5 One 1st-degree melanoma & one 2nd-degree urinary bladder cancer

or

One 1st-degree small intestine cancer

or

Two 1st-degree cervical cancer

10 or

One 2nd-degree stomach cancer & one 2nd-degree urinary bladder cancer

or

One 1st-degree lung cancer & one 1st-degree lip cancer

or

15 Two 1st-degree lip cancers

or

One 1st-degree stomach cancer & one 1st-degree lip cancer

or

One 1st-degree cervical cancer & one 2nd-degree stomach cancer

20 **Example 12**

Validation Procedures

Once a recognizer was constructed, the recognizer was validated. These steps included: 1) review the rules and compare them with any prior rule sets derived by expert knowledge engineering (such as a derived a rule set developed from an expert, such as Dr. Henry T. Lynch); 2) inspect all new cancer family history cases that are consistent with this rule set to determine whether in fact hereditary cancer cases, as diagnosed by experts, are being distinguished from non-cases by the invention; and 3) determine which cases are possibly included which are not hereditary and vice versa (type I and type II errors) and adjust the entire process if need be to improve the

25

outcome.

The process of automated recognizer rule set construction was assessed and validated with *a priori* knowledge which was available for hereditary colon cancer. Similarly the validation for breast cancer, melanoma, and ovarian cancer was repeated.

- 5 Through this assessment process, the automated recognizer development process was refined and was shown to produce a powerful recognizer development technique. Further validation was achieved by running the recognizer against prior cancer cases for which we had Dr. H. T. Lynch's diagnosis regarding their hereditary nature.

- 10 This entire design process was also generalized by positing a universe of genetic principles for all the cases of cancer, and then letting the rule hypothesis component posit rules (i.e., a selection from the genetic principles) which characterize cases of hereditary cancer. For example, for every cancer case, the race, hair color, and so forth along with the age of onset, the number of cancers, and other possible genetic principles were itemized. Then using the exact same process, the rules classify the hereditary
- 15 cancer cases by pertinent genetic principles such as "cancer patients tend to be younger," "have more instances in their family," and so forth. Thus the pertinent genetic principles from among all principles which could be speculated are identified using the same process as presented above.

Example 13

20 Study Evaluating Significant Factor Identification

- This study compared the responses of Dr. Henry T. Lynch and Dr. Stephen J. Lemon of HCI to a set of factors isolated by the Recognizer in its analysis of hereditary colorectal cancer (HCRC) cases. This set of outcomes corresponds to key factors the Recognizer identifies as possibly relevant to incorporate into its decision-making logic to
- 25 recognize HCRC. These factors are defined by the Recognizer as useful in its efforts to construct a set of rules to define HCRC.

A list of 42 cancers was provided to Dr. Lynch and Dr. Lemon, and each was asked separately to mark a ranking using the scale for each cancer as shown in Table 5. The list of cancers was taken from the list which encoded the database used to create the

Recognizer. No Recognizer results were supplied to either physician ahead of time, and no collaboration between the two physicians occurred in selecting a ranking.

Table 5

5

**Rankings Indicating Extent To Which Each
Cancer Reinforces Or Help Confirms A
Hereditary Colon Cancer Syndrome:**

10

- 1 = Definitely - solid data to support relationship
- 2 = Probably - growing evidence of relationship
- 3 = Possibly - speculative relationship at this time
- 4 = Not Relevant - no known relationship

In comparing the results of the Recognizer system's selections of most likely
HCRC-associated cancers with the physicians' ranking, the following results were obtained
in Table 6.

Table 6

20

25

30

HCRC-related cancers listed by any responder	Recognizer Ranking	Dr. Lynch's Ranking	Dr. Lemon's Ranking
Endometrial/Uterine	Definitely	Definitely	Definitely
Kidney/Ureter/Renal Pelvis	Definitely	Definitely	Definitely
Stomach	Definitely	Definitely	Definitely
Small Intestine	Definitely	Definitely	Definitely
Pancreas	Definitely	Definitely	Definitely
Ovarian	Definitely	Definitely	Probably
Liver/Intrahepatic	Not Relevant	Definitely	Definitely
Cervix	Definitely	Not Relevant	Probably
Lymph Nodes	Not Relevant	Not Relevant	Definitely
Appendix	Not Relevant	Not Relevant	Definitely
Gallbladder/Bile Duct/Ampulla of Vater	Not Relevant	Possibly	Definitely

The Recognizer discovered six of seven (86%) of the "definitely related" cancers
which Dr. Lynch identified, and it added one (cervix) that Dr. Lynch did not identify. With
respect to Dr. Lemon, the Recognizer discovered 5 "definitely related" cancers of the nine
which Dr. Lemon identified (56%), and disagreed on four others (lymph nodes,

liver/intrahepatic, gallbladder/bile duct/ampulla of Vater, and appendix). The Recognizer and Dr. Lemon were also in close agreement on two other choices ("definitely" versus "probably" on ovarian and cervix). Hepatobiliary cancer did not specifically appear in the database as a coded choice, although Dr. Lynch and Dr. Lemon both had wished to include it as another choice. The Recognizer did not select either Hepatobiliary-related entry which was available to it (liver/intrahepatic or gallbladder/bile duct/ampulla of Vater) although each was selected by either Dr. Lynch or Dr. Lemon."

The Recognizer was in accord in six of seven cases (86%) on HCRC-related cancers for which Drs. Lynch and Lemon were in accord (ranking of 1 or 2). The system essentially considered 35 cancers as irrelevant, and of these, Drs. Lynch and Lemon were in mutual concurrence, ranking each 3 or 4, for 29 of them (81%). If one considers the frequency of occurrence of the associated cancers for the cancers correctly identified by the Recognizer, (i.e., those for which there was agreement between Dr. Lynch and Dr. Lemon), the Recognizer defined critical attributes for its focus most of the time.

There is a second use of such results by the Recognizer over and above automated HCRC detection. There is clinically diagnostic value in the discovery of associated cancers which help confirm a hereditary pattern. In addition, the identification of associated cancers helps guide future gene discovery efforts, as well as assists in the proper interpretation of gene-testing results.

This first stage evaluation of initial factors selected by the Recognizer suggested that use of such Recognizers is applicable over a wide sampling of typical cases with a very high level of sensitivity in its recognition capability.

Example 14

An Evaluation of Patterns

The purpose of this study was to ascertain how well the Recognizer created valid patterns of HCRC which it uses to evaluate a case.

Drs. Lynch and Lemon were asked to indicate agreement or disagreement with a list of 16 clinical patterns to the extent that each pattern would permit the designation of HCRC for an individual presenting with such a pattern. Each gave an independent

assessment, and each did not know the response of the Recognizer.

The patterns were created by the Recognizer using (a) its convergence to a final list of critical factors in concert with (b) its final output of clinical rules which combine these factors into patterns it uses to characterize HCRC. The results of the sixteen patterns presented for evaluation are given in Table 7 and the sixteen patterns are listed in Table 8.

Table 7

	Would the Following Pattern permit the Conclusion of HCRC?	Dr. Lynch's Response	Dr. Lemon's Response
5	#1	Yes	Yes
	#2	Yes	Yes
	#3	Yes	Yes
	#4	Yes	Yes
	#5	Yes	Yes
	#6	Yes	Yes
10	#7	Yes	Yes
	#8	Yes	Yes
	#9	Yes	Yes
	#10	Yes	Yes
	#11	Yes	Yes
15	#12	Yes	Yes
	#13	Yes	Yes
	#14	Yes	Yes
	#15	Yes	Yes
20	#16	Yes	Yes

Drs. Lynch and Lemon agreed with all 16 patterns the Recognizer had created. The Recognizer's final output was highly sensitive in detecting HCRC.

Table 8

1. All on the same side of the family:
 - a. the proband has colon cancer, and
 - b. there are more than 3 identical cancers (either colon or endometrial), and
 - c. cancer(s) (colon or endometrial) with early onset total a minimum of 6 points
(where cancer by age 35 = 3 points; between 36-45 = 2 points; between 46-49 = 1 point)
2. All on the same side of the family:
 - a. the proband has colon cancer, and
 - b. there are 3 or more of the same cancer (either colon or endometrial) in the same generation, and
 - c. there are 2 or more identical cancers, and
 - d. cancer(s) (colon or endometrial) with early onset total a minimum of 6 points
(where cancer by age 35 = 3 points; between 36-45 = 2 points; between 46-49 = 1 point)

3. All on the same side of the family:
- a. the proband has colon cancer, and
 - b. there are 3 or more of the same cancer (either colon or endometrial) in the same generation, and
 - c. cancer(s) (colon or endometrial) with early onset total a minimum of 6 points
- 5 (where cancer by age 35 = 3 points; between 36-45 = 2 points; between 46-49 = 1 point)
4. All on the same side of the family:
- a. the proband has colon cancer, and
 - b. cancer(s) (colon or endometrial) with early onset total a minimum of 9 points
- (where cancer by age 35 = 3 points; between 36-45 = 2 points; between 46-49 = 1 point)
- 10 5. All on the same side of the family:
- a. the proband has colon cancer, and
 - b. there are 2 or more identical cancers (either colon or endometrial), and
 - c. cancer(s) (colon or endometrial) with early onset total a minimum of 6 points
- (where cancer by age 35 = 3 points; between 36-45 = 2 points; between 46-49 = 1 point)
- 15 6. All on the same side of the family:
- a. the proband has colon cancer, and
 - b. there are 2 or more identical cancers (either colon or endometrial) , and
 - c. there are identical cancers (either colon or endometrial) in 2 or more generations, and
 - d. cancer(s) (colon or endometrial) with early onset total a minimum of 6 points
- 20 (where cancer by age 35 = 3 points; between 36-45 = 2 points; between 46-49 = 1 point)
7. All on the same side of the family:
- a. the proband has colon cancer, and
 - b. there are 3 or more of the same cancer (either colon or endometrial) in the same generation, and
 - c. there are 3 or more identical cancers (either colon or endometrial) in 2 or more generations, and
 - d. cancer (colon or endometrial) with early onset total a minimum of 3 points
- 25 (where cancer by age 35 = 3 points; between 36-45 = 2 points; between 46-49 = 1 point)
8. All on the same side of the family:
- a. the proband has colon cancer, and
 - b. there are 6 or more first degree colon cancers, and
 - c. cancer(s) (colon or endometrial) with early onset total a minimum of 3 points
- 30 (where cancer by age 35 = 3 points; between 36-45 = 2 points; between 46-49 = 1 point)
9. All on the same side of the family:
- a. the proband has colon cancer, and
 - b. there are 3 or more of the same cancer (either colon or endometrial) in the same generation, and

- c. there are 4 or more first degree colon cancers, and
 - d. there is 1 or more second degree colon cancer, and
 - e. cancer(s) (colon or endometrial) with early onset total a minimum of 3 points
(where cancer by age 35 = 3 points; between 36-45 = 2 points; between 46-49 = 1 point)
- 5 10. All on the same side of the family:
- a. the proband has colon cancer, and
 - b. there are 3 or more of the same cancer (colon or endometrial) in the same generation, and
 - c. there are 3 or more first degree colon cancers, and
 - d. there is 1 or more first degree endometrial cancer, and
- 10 e. cancer(s) (colon or endometrial) with early onset total a minimum of 3 points
(where cancer by age 35 = 3 points; between 36-45 = 2 points; between 46-49 = 1 point)
11. All on the same side of the family:
- a. the proband has colon cancer, and
 - b. there are 3 or more of the same cancer (colon or endometrial) in the same generation, and
- 15 c. there are identical cancers (colon or endometrial) in 2 or more generations, and
- d. there is 1 or more second degree colon cancer, and
 - e. cancer(s) (colon or endometrial) with early onset total a minimum of 3 points
(where cancer by age 35 = 3 points; between 36-45 = 2 points; between 46-49 = 1 point)
12. All on the same side of the family:
- a. the proband has colon cancer, and
 - b. there are more than 3 identical cancers (colon or endometrial), and
 - c. there are 2 or more first degree endometrial cancers, and
 - d. cancer(s) (colon or endometrial) with early onset total a minimum of 3 points
(where cancer by age 35 = 3 points; between 36-45 = 2 points; between 46-49 = 1 point)
- 20 13. All on the same side of the family:
- a. the proband has colon cancer, and
 - b. there are 2 or more second degree colon cancers, and
 - c. there is 1 or more first degree endometrial cancer, and
 - d. cancer (colon or endometrial) with early onset total a minimum of 3 points
(where cancer by age 35 = 3 points; between 36-45 = 2 points; between 46-49 = 1 point)
- 25 14. All on the same side of the family:
- a. the proband has colon cancer, and
 - b. there are 3 or more of the same cancer (colon or endometrial) in the same generation, and
 - c. there are 2 second degree colon cancers, and
- 30

d. cancer(s) (colon or endometrial) with early onset total a minimum of 3 points
(where cancer by age 35 = 3 points; between 36-45 = 2 points; between 46-49 = 1 point)

15. All on the same side of the family:

- a. the proband has colon cancer, and
- 5 b. there are 8 or more first degree colon cancers, and
- c. cancer(s) (colon or endometrial) with early onset total a minimum of 3 points
(where cancer by age 35 = 3 points; between 36-45 = 2 points; between 46-49 = 1 point)

16. All on the same side of the family:

- a. the proband has colon cancer, and
- 10 b. there are 3 or more of the same cancer (colon or endometrial) in the same generation, and
- c. there are identical cancers in 2 or more generations, and
- d. there are 4 or more first degree colon cancers, and
- e. there is 1 or more first degree endometrial cancer

Example 15

15 Study Evaluating Recognizer Accuracy

This study extended the focus on the specificity of the Recognizer using those cases which have arisen at several cancer centers which obtain consultation from HCI through an analysis service supported by the Institute. In the past five years, three cases representing definite HCRC patterns and four cases with putative hereditary colorectal cancer patterns have been received, per
20 an analysis of these cases by Dr. Henry Lynch. The goal of the study was to match the already-analyzed cases to the defining patterns created by the Recognizer to see its response compared to Dr. Lynch.

Each case was matched against one or more patterns to determine if it would meet any pattern set. All patterns sets matched by each case were identified. If the case fit none of the
25 patterns created by the Recognizer, minimum additional requirements to match at least one pattern were summarized. The results are shown in Tables 9 and 10.

Table 9

Colon Cancer Cases				
Case Number	Determination by Dr. Lynch	Confirmation by Recognizer	Recognizer Pattern Match	Additional Findings to Match One Pattern
1	Definite Hereditary Pattern	Yes	1,2,3,4,5,6,7	N/A
2	Definite Hereditary Pattern	Yes	5,6	N/A
3	Definite Hereditary Pattern	Yes	1,4,5,6	N/A

Table 10

Colon Cancer Cases				
Case Number	Determination by Dr. Lynch	Confirmation by Recognizer	Recognizer Pattern Match	Additional Findings to Match One Pattern
1	Putative Hereditary Pattern	No	None	Additional early onset less than age 35 to meet #5
2	Putative Hereditary Pattern	No	None	change of ovarian cancer diagnosis to endometrial with age of onset 2 years earlier to meet #13
3	Putative Hereditary Pattern	No	None	One additional colon cancer in same generation to meet #7
4	Putative Hereditary Pattern	No	None	Age of onset of one of the colon cancers prior to age 35 to meet #7 and #11

All the definite patterns of HCRC (N=3) matched one or more of the Recognizer patterns. None of the four putative HCRC cases matched a Recognizer pattern. However the missing data elements required to match at least one pattern were minimal.

Therefore, the Recognizer gives the correct response for all definite HCRC cases, and gives a negative response in all 4 putative HCRC cases. Thus the Recognizer developed was both sensitive and specific for definite HCRC patterns.

While the invention has been disclosed in this patent application by reference to the details of preferred embodiments of the invention, it is to be understood that this disclosure is intended in an illustrative rather than in a limiting sense, as it is contemplated that modifications will readily occur to those skilled in the art, within the spirit of the invention and the scope of the appended claims.

Example 16

Defining a Significant Rule

The construction of the rule set has in practice two components, the development of the first set of rules that use the "genetic principles" $f_{(n)}$ as defined above, and then a second component that defines cancer-presenting patterns among the cases that are contained in the candidate set (i.e., P_i^v).

We constructed an assignment of weights to the rules themselves in order to define which we finally included in the recognizer created for a specific P_i^v .

To accomplish the goal of defining significant rules, we defined the significance function

$$T(x) = \left[\begin{array}{c} 1-10x \\ 10 \end{array} \right]$$

For any rule, let C be the number of candidate cases (i.e., x^h) which meet that rule and let C' be the total number of rules in P_i^v for v and t. Then a rule is significant if

$$T\left(\frac{C}{C'}\right) \leq .05 \quad (\text{significance at a .05 level is preserved})$$

In effect, rules are significant if at least 5% of the cases being considered (i.e., in P_i^v) support or demonstrate the rule.

Example 17

Details of the Methodology: Neural Net Limitations

For completeness, we shall identify some limitations of neural net methodology as a pattern recognizer, to clarify the challenge before us. Neural nets represent complex functions which assign a certain amount of value for a particular attribute of what is being recognized. Thus the color "red" for a rose gives the flower some numerical points;

“having thorns” would also; having any kind of fruit growing would be a negative indicator. By a weighted summing of the positive attributes presented and subtracting the negative, a value is obtained, which if greater than a fixed amount, indicates we have a rose. This methodology requires having possible rose attributes determined and the truth value of the assignment for “rose” (or not) given to the system so that it can balance all its weights to signal a rose. In our situation the detailed attribute universe is not known, in general, and more importantly there is no “labeling” of what constitutes a valid rose. Thus neural net methodology is not applicable to the tasks undertaken.

Another limitation is that the result of the application of neural net methodology is a strictly performance-based network, in the form of essentially a mathematical model that predicts set membership. Such networks do not lend themselves to intellectual clinical model validation although the network’s performance can be measured by testing. Physicians want to know why a claim is made, not just a numerical calculation that it should be made.

15

CLAIMS

WHAT IS CLAIMED IS:

1. A method for determining the existence of a hereditary disease risk in a patient, comprising the steps of:
 - 5 compiling in a computer a database made up of a plurality of records each pertaining to an individual and containing a history of at least one specific disease in a family of that individual, said history including a plurality of parameters relating to each family member identified in said history;
 - defining a plurality of functions each pertaining to said parameters and
 - 10 assigning predetermined weights to said functions based on values of said parameters;
 - for each record in said database, summing the weights obtained for each of said functions to obtain a total value for each of said functions, identifying said record as presenting a hereditary pattern if the total value is above a predetermined
 - 15 threshold, and grouping said identified record into a subset of records;
 - for each record in said database, applying expert knowledge generated rules to independently identify records as presenting hereditary patterns;
 - comparing said independently identified records with said subset of records, and validating defined functions if a predetermined minimum percentage of
 - 20 records in said subset are consistent with said independently identified records; and
 - using validated functions as a recognizer of hereditary disease patterns in a family history of said patient.
2. A method according to claim 1, wherein said plurality of records contain histories
- 25 of instances of cancer.
3. A method according to claim 2, wherein said instances of cancer include breast, ovarian, endometrial, prostate, malignant melanoma and colon cancer.
4. A method according to claim 3, further including the step of assigning weights to particular attributes used in said functions, and defining attributes as significant in the

definition of specific hereditary disease patterns if a minimum percentage of records in said subset are consistent with said independently identified records.

5. A method according to claim 1, wherein an additional record is created in said database for each relative of said individual who is identified as having had said disease.

5

INTERNATIONAL SEARCH REPORT

Int'l Application No

PCT/US 97/01727

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 G06F19/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 G06F

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>PROCEEDINGS OF THE CONFERENCE ON ARTIFICIAL INTELLIGENCE FOR APPLICATIONS, SAN ANTONIO, MAR. 1 - 4, 1994, no. CONF. 10, 1 March 1994, INSTITUTE OF ELECTRICAL AND ELECTRONICS ENGINEERS, pages 164-170, XP000479444 DHIRAJ K PATHAK ET AL: "AUTOMATIC COMPUTATION OF GENETIC RISK" see page 164, left-hand column, line 25 - page 165, right-hand column, line 3 see page 167, left-hand column, line 15 - line 43</p> <p style="text-align: center;">--- -/--</p>	1-5

☒ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

25 April 1997

Date of mailing of the international search report

22.05.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Barba, M

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 97/01727

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>MEDICAL INFORMATICS, ETHICS, CARDIOLOGY, INSTRUMENTATION, SAN DIEGO, OCT. 28 - 31, 1993, vol. 15 PART 2, 28 October 1993, SZETO A;RANGARAJ M RANGAYYAN, page 646/647 XP0000436878 CONSTANTINO I ET AL: "A DATABASE SYSTEM FOR THALASSAEMIA MUTATIONS" see the whole document -----</p>	1-5

1

Form PCT/ISA/218 (continuation of second sheet) (July 1992)